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Abstract
Complications following pelvic radiation are frequently under-reported and inadequately addressed. This overview examines the 
nature and the intensity of complications encountered by cancer survivors; it focuses specifi cally on gastrointestinal and vaginal 
complications, and the problems surrounding the methods of recording and assessing toxicities.
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Introduction
Pelvic malignancies are a common occurrence, with cervix 
carcinoma being one of the most common cancers in women 
in sub-Saharan Africa. The majority of patients present with 
locally advanced disease. This precludes surgical treatment 
and leaves pelvic radiotherapy as the mainstay of curative 
therapy. Adjuvant radiation is also frequently used following 
surgery for both cervical and endometrial carcinoma. 
The benefi ts of treatment outweigh toxicity in most cases. 
However, the late toxicity of treatment can have a signifi cant 
impact on cancer patient survivors. Not only can quality of 
life be affected but additionally ability to work and care for 
family can be compromised, which is of great importance in 
the developing world where many women are the primary 
bread-winners and care-givers. 
The challenge in the management of late toxicities is, fi rstly, 
to recognise the complications, manage them as far as one 
is able and to support the patient. This overview will discuss 
the types of toxicities, frequency and recording methods. The 
details of all toxicity are beyond the scope of this article and 
the focus will be on gastrointestinal and vaginal toxicity, these 
being the most common problems.
Types of late complications
Complications are numerous and varied following pelvic 
radiotherapy (see Table I). Patients may suffer from a single or a 
number of complications. The theoretical cause of late radiation 
damage relates to obliterative endarteritis and resultant 
ischaemia and fi brosis formation.1 Neovascularisation leads 
to the problems of rectal bleeding, haemorrhagic cystitis and 
vaginal contact bleeding. These processes are occasionally 
amenable to specifi c interventions but, on the whole, toxicities 
are ‘managed’, not reversed.
Table I: Types of complications
Site Symptom/sign
Gastrointestinal Rectal bleeding
Diarrhoea
Mucous discharge
Faecal incontinence
Tenesmus
Rectal pain
Flatulence
Cramps
Fistulae
Strictures
Urological Cystitis
Haemorrhage
Frequency
Incontinence
Fistulae
Urethral strictures
Genital Perineal oedema
Telangiectasia
Hormonal Vaginal shortening/narrowing
Sexual dysfunction
Infertility
Menopause
Bone Avascular necrosis
Insuffi ciency fractures
Lymphatic Lymphoedema
  
Gastrointestinal complications are the most readily identifi able 
in the literature and are most frequently studied and reported. 
However, it appears that vaginal complications, paradoxically, 
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are the most frequently reported in prospective studies, 
yet very seldom addressed in retrospective reports in the 
literature. This may very well be due to reluctance by both 
patient and doctor to discuss problems of sexual dysfunction.
Incidence of complications
The true incidence of late effects of radiation in cervix and 
endometrial carcinoma is surprisingly very poorly reported 
in the large international radiation studies. However, these 
studies are probably the best source of data, as the patients 
are rigorously followed-up and evaluated. 
This issue was addressed in the most recent meta-analysis 
regarding chemoradiation in cervix carcinoma.2 The paucity 
of data led the authors to conclude that they were unable to 
assess whether late toxicity is related to choice of treatment. 
In addition it was felt that the data was not representative of 
the real incidence of complications. 
Of the pivotal studies published in 1999 evaluating 
chemoradiation in cervix carcinoma, the late toxicity data were 
noticeably poor. In the Morris study the late grade 4 toxicities 
were 8% in the study arm and 10% in the radiotherapy alone 
arm.3 The majority of toxicities were large bowel or rectum. 
Though one cannot draw reliable conclusions from this 
data, one may reasonably deduce that there is no additional 
toxicity if chemotherapy is added to pelvic radiation in cervix 
carcinoma. 
A national UK audit comprising 1 075 patients published 
by Vale et al evaluated patients with cervix carcinoma who 
received radical radiotherapy, radical chemoradiation or 
surgery followed by postoperative radiotherapy.4 The overall 
grade 3-4 toxicities were 8%, 10% and 5%, respectively. The 
majority of toxicities related to radiation were vaginal. The 
major factor related to increased toxicity was that of increased 
age, though medical comorbidities were not noted.
In the adjuvant radiotherapy setting in endometrial carcinoma, 
a new landmark study, PORTEC-2, laid out the benefi ts of 
reducing pelvic external beam radiation dose by treating with 
vaginal brachytherapy alone.5 Overall, the late gastrointestinal 
toxicity grade 3 was very limited in both the brachytherapy 
alone and the external beam group. Grade1 toxicity was 
signifi cantly more in the external beam arm, but this reduced 
over time. In the subsequent quality of life study of the patients 
recruited in the PORTEC study, patients receiving vaginal 
brachytherapy reported an improved quality of life compared 
to the external beam group.6
The more relevant issue in establishing the incidence of 
late complications may be investigated via patient-reported 
symptoms and not doctor-reported toxicities. Many studies 
show a signifi cant discrepancy between these. A Norwegian 
study showed doctor-reported grade 3-4 toxicity for bowel and 
vaginal toxicity to be 15% and 23%, respectively,7 and patient-
reported severe symptoms were 45% and 58%, respectively.
Quality of life studies examining pelvic radiation are frequently 
published and all appear to show that radiation therapy 
has an adverse effect on the day-to-day life of cancer 
survivors.8,9,10,11 This leads us to the conclusion that, despite 
the best attempts at clinician-recorded toxicity scores, we are 
vastly underestimating the impact of toxicity on the lives of 
our patients.
Reporting of late toxicities
The above clearly points to a failure in the accurate reporting 
of late effects. In some studies, this may be due to poor 
documentation and, in meta-analyses, there is a lack of 
comparability due to the wide variety of toxicity scores in 
use. In general, toxicities are graded 0-5, with grade 0 being 
no symptoms and grade 5 being death. The most commonly 
used are the RTOG,8 CTC v29 and LENT-SOMA.10 Of these, 
the RTOG is the simplest but least detailed, and the LENT-
SOMA is the most extensive but entirely unsuited for day-
to-day use in the busy clinic setting. Many studies use their 
own toxicity scores, as investigators have found the above to 
be inadequate. In addition, in the developing world, patient-
based questionnaires are not appropriate, due to language 
and literacy constraints.  In summation, the recording of late 
toxicity is very unsatisfactory. 
There has been a move towards cooperation and cohesion 
and the production of a common record and one that is simple 
to use. Dische et al proposed that grading of morbidity can 
be more simply attributed to the effect of that symptom on 
the patient’s day-to-day life.11 Criteria taken into account are 
medication and effi cacy, changes in lifestyle, inpatient care, 
and surgery. However, even this more pragmatic approach is 
time consuming in a pressurised clinic setting. 
This author uses an abridged version of the RTOG late toxicity 
score including the most common side effects involving the 
upper gastrointestinal, lower gastrointestinal, bladder, skin 
and vaginal sites. This quick and easy- to-use scoring system 
helps to identify and treat those who are suffering from side 
effects, including those that, as clinicians, we may overlook. It 
is an aid to record keeping and documentation of the impact 
of treatment. Until such time as there may be a common 
toxicity scoring system, it is imperative that clinicians pro-
actively adapt some form of scoring system.
Management of individual toxicities
Gastrointestinal toxicity
Rectal bleeding is the most readily reported symptom reported 
by patients when one examines the literature. In addition, 
change in bowel habit, a mucous discharge and rectal pain 
may occur. Where resources allow, patients should be offered 
the opportunity to be referred to gastroenterology colleagues 
for a detailed review if they develop any related symptoms. 
In all patients, a sigmoidoscopy or colonoscopy should be 
performed and suspicious areas may be biopsied if there 
is concern that a second pathology may be present, such 
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as malignancy. The treatment of rectal bleeding has been 
approached in a varied manner, as seen in Table II.
Table II: Interventions for the treatment of gastrointestinal toxicity
Intervention
5-aminosalicylates 
Corticosteroids
Sucralfate
Metronidazole
Formalin enemas
Laser
Heater probe
Hyperbaric oxygen
Surgical resection
A systematic review by Denton et al was undertaken to 
identify the effective components of this long “shopping list” 
of interventions.12 It was found that trials were very limited, 
often small, single institution interventional studies, and very 
few compared the interventions to a placebo. However, it was 
found that metronidazole at a dose of 400 mg three times a 
day for a year was superior to mesalazine and betamethasone 
enemas alone (study population n = 60). Furthermore, rectal 
sucralfate was superior to oral sulphasalazine and rectal 
steroids for four weeks (study population n = 37). There were 
no reported studies on the use of formalin, but individual 
reports suggest some success. There is no clear guidance 
on when to institute rectal formalin and, in this author’s 
institution, it is attempted if sucralfate enemas fail. 
Medical treatments are, on the whole effective, however 
in the minority of cases where this approach fails laser 
therapy, hyperbaric oxygen and surgery may need to be 
considered. Hyperbaric oxygen has been increasingly 
the focus of international studies. Clarke et al reported 
a randomisation of 120 patients with refractory radiation 
proctitis.13 The results showed a significant improvement 
in healing in the treatment arm (responders per clinical 
assessment 88.9% vs 62.5%; p = 0.0009). Resource 
constraints may preclude the use of hyperbaric oxygen, 
though there are centres linked to academic institutions 
in South Africa. In the Western Cape, these services are 
offered at a reduced rate for state patients.
Surgical intervention with bowel resection or colostomy 
formation is necessary when fi stula formation or bowel 
obstruction occurs, or medical therapy fails. Details of surgical 
management are beyond the scope of this review, but it is 
important to note that cooperation between radiotherapists 
and surgical colleagues is essential in order to provide best 
patient care.
Vaginal toxicity/sexual dysfunction
Vaginal toxicity may include shortening, narrowing due to 
fi brotic bands, teleangiectasia and vaginal bleeding, dryness 
secondary to local changes and menopausal effects, and 
associated dyspareunia. 
Figure 1: Radiation effect in a vault smear.  Large cells with abundant 
cytoplasm are arranged in a monolayered sheet. Some of the cells are 
multinucleated.  Many neutrophils are present in the cytoplasm of the 
large cells. Papanicolaou stain (original magnifi cation 400x). 
Figure 2: Radiation effect in a vault smear.  The nucleus of the cell 
is markedly enlarged and has a bizarre appearance but the nuclear-
to-cytoplasmic ratio is preserved.  Cytoplasmic vacuolisation can be 
seen (07:00). Papanicolaou stain (original magnifi cation 1000x).
For patients that have been, and remain, sexually active after 
pelvic radiation, this is a signifi cant toxicity with a major impact 
on quality of life and social interaction. Vistad et al, as detailed 
above, found that 58% of patients investigated in a self-report 
study complained of signifi cant vaginal discomfort.7 Essentially, 
6 out of every 10 patients that enter the clinic are experiencing 
a toxicity that is largely ignored. In addition to the physical 
changes, there are additional psychosexual issues, with fear 
of inducing a relapse, fear of pain, and sexual aversion post-
therapy.14 Contributing to this is the failure of the clinician to 
adequately address these issues, both prior to and after therapy. 
Both clinician and patient may be hesitant to enter into a 
discussion due to embarrassment, lack of rapport, opposite sex, 
and lack of knowledge. Once again language, cultural barriers 
and pressure on clinic time are additional obstacles in the 
developing world setting.
Thought must be given to how these issues can be addressed. 
Firstly, as clinicians we must remove the taboo around 
Review:Long-term complications of pelvic radiotherapy Review:Long-term complications of pelvic radiotherapy Review:Long-term complications of pelvic radiotherapy
65
Review:Long-term complications of pelvic radiotherapy
2010 Vol 2 No 2South Afr J Gynaecol Oncol
discussions of physical and psychosexual problems, so that 
patients feel they can bring these issues to clinic. Secondly, 
we must consider practical solutions in order to ease the 
patient’s discomfort as detailed in Table III. It must be noted 
that the continuation of normal sexual activity is the best 
form of prevention of vaginal stenosis. Furthermore, if at all 
possible, attempts should be made to engage the patient’s 
partner in discussion and education.
Table III: Interventions for the treatment of vaginal toxicity
Intervention
Topical oestrogen
Hormone replacement therapy
Lubricants
Vaginal dilators
Conclusions
In conclusion, it is clear that pelvic radiation impacts the quality 
of our patients’ lives. It appears that we are underestimating 
the true incidence and severity of these complications, due 
to imperfect scoring systems and poor communication with 
patients. In the developing world, we are further restricted by 
language and cultural barriers, poor follow-up attendance and 
the unknown impact of HIV infection on late complications. 
As far as time allows in busy clinical practice, we must 
enquire specifi cally about symptoms of toxicity, and take 
responsibility to address not only the physical problems, but 
also the psychological impact that pelvic radiation has had on 
our cancer survivors.
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